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Abstract Phimosis has been defined as unretractable
foreskin without adherences and/or a circular band of
tight prepuce preventing full retraction. The aim of this
study is to evaluate the efficacy (response rate) of
topical steroids for the treatment of tight phimosis at
different age stages. After using the same medication
with different dosage schemes, a retrospective analysis
was carried out to assess the efficacy of topical steroids
in the treatment of tight phimosis. Patients were di-
vided into three groups: group A (betamethasone
scheme A), group B (betamethasone scheme B) and
group C (control group). Remission of phimosis, with a
complete exposure and without a narrowing behind the
glans, was considered a complete response to treat-
ment. The outcomes were then related to dosage
scheme and patient’s age. The dosage for group A was
more effective than the dosage for groups B and C
(control group). Phimosis resolved in 90% (group A),
72% (group B) and 56% (group C) of cases. A suc-
cessful treatment was closely related to the age of pa-
tients at the beginning of steroid application. The
results showed that treatment with topical steroids,
which in general gives good results, proved to be much
more successful in patients aged between 4 and 8 years,
suggesting the efficacy of an early beginning of the
treatment.
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Introduction
Phimosis has been defined as unretractable foreskin of
the prepuce, preventing complete exposure of the glans
[1].
In the literature, topical steroids are now commonly
considered as an effective treatment for this condition
[1–11], even if there are still doubts about the most
effective medication, the most suitable length of
application and about the number of attempts before
surgical correction of phimosis becomes necessary.
So far no research study has given any indications in
terms of patient’s age or has suggested a possible
relation between resolution of phimosis and age of
patients treated.
In the literature there are studies showing that the
physiological retractability of the prepuce is age
dependent: it is virtually absent in the first months of
life, gradually increasing up to 11–15 years of age,
when prepuce retraction is complete [12–14].
The aim of this study is to evaluate the efficacy of
topical steroids administered with different dosage
schemes in patients with tight phimosis at different age
stages.
Materials and methods
The results obtained between January 2001 and June
2005 were retrospectively analyzed after treating for
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tight phimosis 298 patients aged between 4 and
14 years (mean age 7 years).
No retraction of the prepuce with a flaccid or erect
penis was defined as tight phimosis.
Study inclusion criteria, for each group were, tight
phimosis never treated with topical steroids, absence of
previous urinary tract infections or balanoposthitis, age
>3 years and no hormone therapy administered before
or during the study. Patients were randomised into the
treatment groups at our outpatients department.
This study was approved by the ethics committee of
the authors’ institution and the patients’ parents had to
sign a written informed consent form.
In the period 2001–2003, patients with phimosis
treated with topical steroids received betamethasone
0.05% once a day for 30 days (group B), while in the
period 2003–2005 patients received betamethasone
0.05% twice a day for 15 days, and then once a day for
the following 15 days (group A) [15].
For all patients under treatment, steroid application
was concomitant with stretching methods starting from
day 7.
Patients were divided into three groups: group A
(treatment period 2003–2005, scheme A), 104 patients;
group B (treatment period 2001–2003, scheme B), 94
patients; group C (control group) 100 patients.
The control group included all patients who did not
receive topical steroids: 45 patients in the period 2001–
2003 and 55 patients in the period 2003–2005. These
patients, also affected by tight phimosis, were treated
with stretching methods only.
None of the study patients had received either top-
ical or systemic treatment with corticosteroids before,
or was affected by other pathologies. No patients from
group A and B received more than three cycles.
Stretching methods
All patients (or their parents) had to retract the pre-
puce gently, when no pain was reported, without
forcing it for 1 min at least four times a day for a
month.
After the end of topical treatment, stretching
methods had to be carried out daily together with good
personal hygiene using neutral soap. Follow-up visits
were carried out 10 days after the end of each treat-
ment (group A, B and C); and then after 3 and
6 months at the outpatients department.
The patients showing resolution of tight phimosis,
with complete exposure and without a narrowing ring
behind the glans, were considered as responders to the
treatment.
After further dividing the patients into different age
groups (up to 4 years, between 4 and 6, between 6 and
8, between 8 and 10, between 10 and 12 and between 12
and 14 years), the Authors analyzed the results ob-
tained according both to dosage scheme and age of
patients. The response rate (resolution of phimosis)
was related to patient’s group and age range.
Statistical analysis was performed using the Fisher
exact test and the chi-square test; a P value less than
0.01 was considered significant.
Results
Between January 2001 and June 2005, 298 patients, all
affected by tight phimosis, adhered to our protocol.
The results collected from all three groups after the
last follow-up visit (6 months) were retrospectively
analyzed according to the different dosage schemes
used for group A and B, and the age of patients.
(Tables 1, 2)
An external clinician, blinded to the treatment, as-
sessed the patients before the study doctors during the
follow-up visits at the outpatients department.
Figures 1 and 2 show the mean age of patients af-
fected by phimosis and their distribution per group of
treatment. As it is shown in Table 1 and Fig. 2, the
three groups were homogeneous for number of pa-
tients and distribution per age range.
Treatment
All patients followed the treatment with a compliance
of 100%. No patient from group A and B reported any
side effect caused by the treatment. There were posi-
tive results for each group also 3 and 6 months after
the end of treatment.
Group A: among 104 patients, 93 patients showed a
complete remission of phimosis, while 11 patients
did not show a complete remission (narrow ring or
Table 1 Study group
Age (year) Patients
Group A Group B Group C
Until 4 16 12 16
4–6 36 28 30
6–8 24 20 20
8–10 12 14 14
10–12 8 14 10
12–14 8 6 10
Total 104 94 100
Age distribution at first visit
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partial exposition of the glans). Thirty-eight percent-
age of patients received three cycles of treatment,
44% received two cycles and 18% received only one
cycle of treatment with topical steroid.
Group B: among 94 patients, 68 patients showed
complete remission of phimosis, 20 patients showed
partial remission and six patients did not show any
improvement. Forty-six percentage of patients re-
ceived three cycles of treatment, 33% received two
cycles and 21% received only one cycle of treatment
with topical steroid.
Group C: among 100 patients, 56 patients showed
either a partial or complete remission of phimosis,
while 44 patients did not show any improvement.
Efficacy of treatment
Figure 3 shows that the resolution of tight phimosis
had an equal distribution per age range in both groups,
although the treatment received by group A proved to
be more effective than the treatments received by
groups B and C.
This means that the treatment used for group A is
more effective than the treatments used for groups B
and C.
Statistical analysis
The groups observed for this study were homogeneous
for number and age of patients.
There was a statistically significant relationship be-
tween resolution of phimosis and age range (P < 0.01).
Better results were observed in the age range 4–8 years
(P < 0.01).
There was also a statistically significant relationship
between the efficacy of treatment and treatment group.
The treatment with topical steroids (groups A and B)
was more effective than the treatment without topical
steroids (group C) (P < 0.01).
Dosage scheme A was more effective than dosage
scheme B (P < 0.01) which, on the other hand, was
more effective than the treatment received by group C
(P < 0.01).
Table 2 Outpatients department results after 6 months
Age (year) Good Poor
A B C A B C
Until 4 16 10 10 0 2 6
4–6 34 24 22 2 4 8
6–8 22 16 12 2 4 8
8–10 10 9 5 2 5 9
10–12 6 7 3 2 7 7
12–14 5 2 4 3 4 6
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There is not a statistically significant relationship
between response rate, patient’s group, age range and
number of cycles performed (P > 0.01).
Discussion
During the years, scientific investigations have been
focused on the development of methods to optimize
the efficacy and, specifically, the anti-inflammatory
qualities of topical steroids.
At present, the ideal topical steroid has yet to be
synthesized since topical steroids should be able to go
through the horny layer of the skin and leave suitable
steroid concentration on the skin, avoiding high serum
concentrations. For instance, betamethasone, com-
monly known as a fifth generation steroid, is a typical
example of a powerful molecule, which can obtain high
concentrations on the skin and, consequently, a high
probability of developing local side effects.
Steroid action on the skin
There may be two possible mechanisms involved in the
action of steroid creams resulting in the resolution of
phimosis.
First, there is an anti-inflammatory and immuno-
suppressive effect. Corticosteroids stimulate the
production of lipocortin. Lipocortin then inhibits the
activity of phospholipase A2, which releases
arachidonic acid (the precursor of prostanoids and
leukotrienes, mediators of skin inflammation) from
phospholipids. Corticosteroids are known to inhibit the
early phenomena of the inflammatory process (oede-
ma, fibrin deposition, capillary dilatation, migration of
leucocytes into the inflamed area and phagocyte
activity) as well as its later manifestations (prolifera-
tion of capillaries and fibroblasts, depletion of collagen
and cicatrisation). A major antifibrotic effect is the
reduction of Type I and III collagen synthesis in many
cell types, including fibroblasts [16, 17].
Second, there is a skin thinning effect. Steroids inhibit
the dermal synthesis of glycosaminoglycans by fibro-
blasts, resulting in the loss of ground substance sub-
sequent to a decreased binding effect of tissue fluid to the
hyaluronic acid. Consequently, the dermal extracellular
matrix is reduced and collagen and elastin fibers become
tightly packed and rearranged. Steroids have an active
role in the inhibition of collagen synthesis and have
antiproliferative effects on the epidermis.
Skin absorption of topical steroids and their activity
depend on a number of factors: integrity of the horny
layer of the skin, vehicle and steroid receptors in the
cytoplasm of target cells.
Steroid receptors and resistance
Steroids act through specific receptors in the cell nu-
cleus. After activating these receptors through a com-
plex mechanism of activation of different co-factors,
the action of steroids produces anti-inflammatory
substances and inhibits pro-inflammatory substances
[18, 19].
Apparently, the action of these receptors depend on
a number of factors, including their tissue concentra-
tion and steroid activation capacity. Recent studies
showed that different steroids activate the receptors in
a different way, producing a steroid-specific tissue re-
sponse [20–27].
All the above studies indicate that the efficacy of
steroids seems to be compromised by the development
of a specific tissue resistance. If we exclude a genetic
(family) resistance, tissue resistance to topical steroids
is closely related to a number of factors: long time of
application, pharmacokinetic abnormalities, antibodies
to lipocortin-1, cellular abnormalities and abnormali-
ties in GR function [25, 28, 29].
Phimosis and response rate
All the above considerations explain quite easily why
topical steroids may give different results depending on
the patients treated. Previous anatomic studies de-
scribed physiological changes of the prepuce during
early childhood affecting the quality of the Dartos
fibres.
After circumcision it was possible to observe a sta-
tistically significant increase in the volumes of smooth
muscle fibres in the younger groups and of elastic fibres
in the older groups were observed [30].
If phimosis is characterized by a progressive fibrosis
preventing the physiological retraction of the prepuce,
probably the efficacy of a treatment with topical ste-
roids may depend on the efficacy of the medication on
a specific patient as well as on the concentration of
receptors in a non-receptive tissue. This would explain
why some patients respond better than others to a
treatment with specific topical steroids, as many sur-
veys have shown.
This study assessed two groups of patients treated
with the same topical steroid cream administered with
different dosage schemes. Data analysis showed that: (1)
bethametasone, like other topical steroids, is an efficient
treatment for phimosis; (2) treatment with topical
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steroids is more successful than stretching alone; (3) the
dosage schemes used in the study gave different positive
results, probably because receptor saturation is different
after a constant application (once daily) of topical
steroid cream; (4) a double administration for 15 days
and then a single administration for the following
15 days (group B) would allow a continuous activity of
skin receptors, preventing drug-mediated resistance,
through a modulated activation of quiescent receptors in
the second phase of the treatment; (5) an early treatment
with topical steroids showed much better results, with a
higher responce rate between 4 and 8 years of age.
Conclusions
After considering the data collected during this study,
the Authors suggest an early beginning of the treat-
ment. Further randomized studies would be appropri-
ate to understand whether the efficacy of topical
steroids may depend on the patient and the medication
used for the treatment.
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